Research Article
The Prognostic Potential of Neurokinin 1 Receptor in Breast Cancer and Its Relationship with Ki-67 Index
Table 2
Association between neurokinin 1 receptor expression level and clinicopathological parameters.
| | Parameters | Low or no expression | High expression | | | Percentage (%)/ | Percentage (%)/ |
| | Age (years) | | | 0.350 | | Molecular subtype | | | 0.493 | | HER2-enriched | 26 (24.1) | 16 (28.6) | | Luminal A | 30 (27.8) | 10 (17.9) | | Luminal B | 28 (25.9) | 14 (25.0) | | Triple negative | 24 (22.2) | 16 (28.6) | | Grade | | | 0.021 | | I | 8 (7.4) | 0 (0.0) | | II | 34 (31.5) | 12 (21.4) | | III | 66 (61.1) | 44 (78.6) | | Tumor volume (cm3) | | | 0.169 | | TNM stage | | | 0.427 | | I | 4 (3.7) | 3 (5.6) | | II | 34 (31.8) | 11 (20.4) | | III | 34 (31.8) | 22 (40.7) | | IV | 35 (32.7) | 18 (33.3) | | pT stage | | | 0.628 | | T1 | 8 (7.4) | 5 (8.9) | | T2 | 60 (55.6) | 28 (50.0) | | T3 | 28 (25.9) | 19 (33.9) | | T4 | 12 (11.1) | 4 (7.1) | | pN stage | | | 0.136 | | N0 | 27 (25.5) | 17 (32.1) | | N1 | 32 (30.2) | 7 (13.2) | | N2 | 20 (18.9) | 13 (24.5) | | N3 | 27 (25.5) | 16 (30.2) | | Distant metastasis | | | 0.860 | | M0 | 72 (67.3) | 35 (64.8) | | M1 | 35 (32.7) | 19 (35.2) | | Axillary lymph node metastasis | | | 0.356 | | Negative | 27 (25.2) | 18 (32.7) | | Positive | 80 (74.8) | 37 (67.3) | | Lymphovascular invasion | | | 1.000 | | Negative | 36 (34.0) | 17 (32.7) | | Positive | 70 (66.0) | 35 (67.3) | | ER status | | | 0.249 | | Negative | 50 (46.3) | 32 (57.1) | | Positive | 58 (53.7) | 24 (42.9) | | PR status | | | 0.249 | | Negative | 50 (46.3) | 32 (57.1) | | Positive | 58 (53.7) | 24 (42.9) | | HER2 status | | | 0.742 | | Negative | 54 (50.0) | 26 (46.4) | | Positive | 54 (50.0) | 30 (53.6) | | DCIS history | | | 0.331 | | Absent | 23 (21.7) | 16 (29.6) | | Present | 83 (78.3) | 38 (70.4) | | Family history | | | 0.270 | | No | 74 (81.3) | 32 (72.7) | | Yes | 17 (18.7) | 12 (27.3) | | Adjuvant chemotherapy | | | 0.598 | | No | 2 (2.4) | 2 (4.9) | | | Yes | 81 (97.6) | 39 (95.1) | | | Adjuvant radiotherapy | | | 0.699 | | No | 49 (59.0) | 26 (63.4) | | | Yes | 34 (41.0) | 15 (36.6) | | | Hormonal therapy | | | 0.252 | | No | 38 (45.8) | 24 (58.5) | | | Yes | 45 (54.2) | 17 (41.5) | | | Immunotherapy | | | 1.000 | | No | 79 (95.2) | 39 (95.1) | | | Yes | 4 (4.8) | 2 (4.9) | | | Ki-67 | | | 0.012 | | Low | 71 (65.7) | 25 (44.6) | | High | 37 (34.3) | 31 (55.4) |
|
|
ER: estrogen receptor; PR: progesterone receptor; DCIS: ductal carcinoma in situ. values in bold are those <0.05. |
